Bat virome

SymCheck Releases COVID-19 Health Safety Compliance Platform Supporting Hospitality Industry Recovery

Retrieved on: 
Wednesday, February 10, 2021
Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Infectious diseases, Medical specialties, Animal diseases

NEW YORK, Feb. 10, 2021 /PRNewswire-PRWeb/ -- SymCheck , an automated mobile health screening, assessment and compliance software platform, announced its commercial release today after several months of successful customer trials.

Key Points: 
  • NEW YORK, Feb. 10, 2021 /PRNewswire-PRWeb/ -- SymCheck , an automated mobile health screening, assessment and compliance software platform, announced its commercial release today after several months of successful customer trials.
  • "SymCheck automates everything I have to do to comply with the health department's screening and recordkeeping requirements for indoor dining.
  • SymCheck is an automated health screening, assessment and compliance software platform designed to verify that individuals do not pose an elevated risk for exposing others to illness.
  • SymCheck eliminates the required paperwork, prevents on-site exposure, protects personal health information and documents best practices to protect against SARS-CoV-2 or other transmission.

Leading Health Organizations call on OSHA and CDC to Issue Guidance on Preventing Occupational Exposures Due to Aerosol Transmission of SARS CoV-2

Retrieved on: 
Wednesday, February 10, 2021
Coronaviridae, Sarbecovirus, Health, Disease transmission, COVID-19, Occupational safety and health, Bat virome, Severe acute respiratory syndrome, Airborne transmission, Respirator, Workplace hazard controls for COVID-19, Isolation

As of October 2020, the World Health Organization (WHO) and the CDC had yet to alter protection guidelines for workers and communities to address SARS-CoV-2 aerosol transmission.

Key Points: 
  • As of October 2020, the World Health Organization (WHO) and the CDC had yet to alter protection guidelines for workers and communities to address SARS-CoV-2 aerosol transmission.
  • The Joint Consensus Statement , endorsed by AIHA and the other organizations, summarizes what occupational health professionals and scientists currently know about airborne SARS-CoV-2 transmission and outlines recommendations that call for regulation, research, and funding towards airborne transmission prevention practices.
  • These recommendations include:
    That in light of concerns about aerosol transmission of SARS-CoV-2, the CDC and state health departments review their guidance for occupational prevention and respiratory protection.
  • That OSHA continues the rulemaking process for an infectious disease standard applicable to all industries and issues it as soon as possible.

Newly Released Antiviral Fabric from SQ Group Kills COVID-19 Virus

Retrieved on: 
Wednesday, February 10, 2021
Medicine, Medical specialties, Health sciences, Zoonoses, Human coronavirus 229E, Coronavirus, Bat virome, Sarbecovirus, Jinan, Nano, Antiviral drug, Severe acute respiratory syndrome

JINAN, China, Feb. 10, 2021 /PRNewswire/ -- Jinan Shengquan Group Share Holding Co., Ltd. (SQ Group) in collaboration with Hong Kong Nano and Advanced Materials Institute (NAMI) released its latest scientific research result, a newly unveiled antiviral, antibacterial fabric.

Key Points: 
  • JINAN, China, Feb. 10, 2021 /PRNewswire/ -- Jinan Shengquan Group Share Holding Co., Ltd. (SQ Group) in collaboration with Hong Kong Nano and Advanced Materials Institute (NAMI) released its latest scientific research result, a newly unveiled antiviral, antibacterial fabric.
  • Recently in Jinan, an appraisal meeting was held to discuss the scientific and technological achievements of SQ Group's Nano-VTC antibacterial, antiviral material.
  • The newly developed Nano-VTS antibacterial and antiviral fabric effectively kills 3 of the 7 currently known coronaviruses that can infect humans, COVID-19, SARS, and HCoV-229E.
  • Currently, SQ Group masks produced with this fabric have already passed the EU mask standard CWA17553-2020 test and entered the market.

Newly Released Antiviral Fabric from SQ Group Kills COVID-19 Virus

Retrieved on: 
Wednesday, February 10, 2021
Medicine, Medical specialties, Health sciences, Zoonoses, Human coronavirus 229E, Coronavirus, Bat virome, Sarbecovirus, Jinan, Nano, Antiviral drug, Severe acute respiratory syndrome

JINAN, China, Feb. 10, 2021 /PRNewswire/ -- Jinan Shengquan Group Share Holding Co., Ltd. (SQ Group) in collaboration with Hong Kong Nano and Advanced Materials Institute (NAMI) released its latest scientific research result, a newly unveiled antiviral, antibacterial fabric.

Key Points: 
  • JINAN, China, Feb. 10, 2021 /PRNewswire/ -- Jinan Shengquan Group Share Holding Co., Ltd. (SQ Group) in collaboration with Hong Kong Nano and Advanced Materials Institute (NAMI) released its latest scientific research result, a newly unveiled antiviral, antibacterial fabric.
  • Recently in Jinan, an appraisal meeting was held to discuss the scientific and technological achievements of SQ Group's Nano-VTC antibacterial, antiviral material.
  • The newly developed Nano-VTS antibacterial and antiviral fabric effectively kills 3 of the 7 currently known coronaviruses that can infect humans, COVID-19, SARS, and HCoV-229E.
  • Currently, SQ Group masks produced with this fabric have already passed the EU mask standard CWA17553-2020 test and entered the market.

Athletica Sport Systems Inc. and Red Barn Healthcare Sign Reseller Agreement to Make Ice Sports Safer

Retrieved on: 
Tuesday, February 9, 2021
Infectious diseases, Health, Sarbecovirus, Atypical pneumonias, Occupational safety and health, Medical specialties, Pandemics, Bat virome, Severe acute respiratory syndrome, COVID-19 pandemic, Coronavirus disease, Coronavir

Currently, ice facilities are operating at limited capacity due to the Coronavirus pandemic.

Key Points: 
  • Currently, ice facilities are operating at limited capacity due to the Coronavirus pandemic.
  • The distribution agreement will focus initially on tools that address the ongoing pandemic caused by SARS-CoV-2, the virus that causes COVID-19.
  • Red Barn Advisory Team Member and Senior Advisor to Red Barn Healthcare, Bob Fallen, sought out a distribution partnership with Athletica Sport Systems.
  • "Athletica is the recognized leader in safety and innovation in the ice sport facilities market," said Fallen.

NIH Sponsored Study at Stanford University School of Medicine to Utilize Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay to Evaluate Immune Responses in Pediatric Patients with COVID-19

Retrieved on: 
Tuesday, February 9, 2021
Natural sciences, Chemistry, Physical sciences, Flow cytometry, Laboratory techniques, Sarbecovirus, Bat virome, Fluidigm, Mass cytometry, Cytometry Part A, Severe acute respiratory syndrome, Assay

Krams is a lead researcher on the study, along with Olivia M. Martinez, PhD, Professor of Surgery at Stanford Medicine.

Key Points: 
  • Krams is a lead researcher on the study, along with Olivia M. Martinez, PhD, Professor of Surgery at Stanford Medicine.
  • The study is expected to enroll about 250 SARS-CoV-2 infected patients under age 21 from diverse racial and ethnic backgrounds.
  • Data from this study will join a growing body of peer-reviewed research based on mass cytometry and Maxpar technologies.
  • Fluidigm, theFluidigmlogo, Cell-ID, CyTOF, Direct, Helios, Immune Profiling Assay, Maxpar, and Pathsetter are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries.

Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses

Retrieved on: 
Thursday, February 4, 2021
Coronaviridae, Nidovirales, Sarbecovirus, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Coronavirus, Human coronavirus 229E, Middle East respiratory syndrome–related coronavirus

An additional panel has been included containing epitopes of high genetic homology to endemic human coronaviruses (HCoV).

Key Points: 
  • An additional panel has been included containing epitopes of high genetic homology to endemic human coronaviruses (HCoV).
  • This panel will facilitate research into the role HCoV play in the immune response to SARS-CoV-2 infection.
  • A recent report on health care workers in the US demonstrated cross-reactive T cell responses between HCoV and SARS-CoV-2 infections1.
  • T-SPOT, T-Cell Xtend, the Oxford Immunotec logo, and T-SPOT Discovery are trademarks of Oxford Immunotec Limited.

EmitBio Demonstrates New Treatment Is Effective Against Multiple Types Of Coronavirus

Retrieved on: 
Thursday, February 4, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Animal diseases, Bat virome, In Saudi Arabia, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Coronavirus, Middle East respiratory syndrome–related coronavirus, Variants of SARS-CoV-2, Coronavir

These findings indicate a likelihood the company's technology will also be effective against SARS-CoV-2 variants (mutations).

Key Points: 
  • These findings indicate a likelihood the company's technology will also be effective against SARS-CoV-2 variants (mutations).
  • "Over the last 20 years we have seen three life-threatening coronavirus outbreaks, SARS-CoV-1, MERS-CoV, and now SARS-CoV-2 the virus that causes COVID-19," stated Neal Hunter, Executive Chairman of EmitBio.
  • "Having this countermeasure at-the-ready will not only help current COVID-19 patients but will also provide protection against future outbreaks.
  • The research team at EmitBio welcomes inquiries and offers of scientific collaboration from the global research community.

BioVaxys SARS-CoV-2 Vaccine Candidate BVX-0320 Stimulates Neutralizing Antibodies To Live COVID-19 Virus

Retrieved on: 
Tuesday, February 2, 2021
Sarbecovirus, Zoonoses, Animal diseases, Nidovirales, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Coronavirus disease, COVID-19 vaccine, Reporter virus particles

It's worth noting that OSU is one of the few institutions that has the laboratory capability to study live SARS-CoV-2 virus.

Key Points: 
  • It's worth noting that OSU is one of the few institutions that has the laboratory capability to study live SARS-CoV-2 virus.
  • Plaques are produced by infection of cultured human cells by a live SARS-CoV-2 virus.
  • For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

BioVaxys SARS-CoV-2 Vaccine Candidate BVX-0320 Stimulates Neutralizing Antibodies To Live COVID-19 Virus

Retrieved on: 
Tuesday, February 2, 2021
Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Bat virome, Severe acute respiratory syndrome, Coronavirus disease

It's worth noting that OSU is one of the few institutions that has the laboratory capability to study live SARS-CoV-2 virus.

Key Points: 
  • It's worth noting that OSU is one of the few institutions that has the laboratory capability to study live SARS-CoV-2 virus.
  • For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and US OTC: LMNGF.